modelRotigotine
Extends from Pharmacolibrary.Drugs.ATC.N.N04BC09.
Information
| name: | Rotigotine | |
| ATC code: | N04BC09 | route: | transdermal |
| compartments: | 1 | |
| dosage: | 8 | mg |
| volume of distribution: | 84 | L |
| clearance: | 12 | L/h |
| other parameters in model implementation | ||
Rotigotine is a non-ergoline dopamine agonist used in the treatment of Parkinson's disease and restless legs syndrome. It is administered via a transdermal patch and is approved for clinical use in many countries.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult subjects and patients with Parkinson's disease following repeated transdermal administration.
References
Cawello, W, et al., & Funaki, T (2016). Pharmacokinetics, safety, and tolerability of rotigotine transdermal system in healthy Japanese and Caucasian subjects following multiple-dose administration. European journal of drug metabolism and pharmacokinetics 41(4) 353–362. DOI:10.1007/s13318-015-0273-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25773763
Cawello, W, et al., & Funaki, T (2014). Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects. Clinical drug investigation 34(2) 95–105. DOI:10.1007/s40261-013-0150-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24178238
Liu, Y, et al., & Elshoff, JP (2018). Pharmacokinetics, Tolerability, and Bioequivalence of Two Formulations of Rotigotine in Healthy Chinese Subjects. Clinical therapeutics 40(7) 1108–1121.e8. DOI:10.1016/j.clinthera.2018.05.009 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30098648
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)